Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity

We have previously identified a phosphorothioate oligonucleotide (PS-ODN) that inhibited epidermal growth factor receptor tyrosine kinase (TK) activity both in cell fractions and in intact A431 cells. Since ODN-based TK inhibitors may have anti-cancer applications and may also help understand the no...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical pharmacology 2002-06, Vol.63 (12), p.2187-2195
Hauptverfasser: Akhtar, Saghir, Dunnion, Debbie, Poyner, David, Ackroyd, John, Bibby, Mike, Double, John
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2195
container_issue 12
container_start_page 2187
container_title Biochemical pharmacology
container_volume 63
creator Akhtar, Saghir
Dunnion, Debbie
Poyner, David
Ackroyd, John
Bibby, Mike
Double, John
description We have previously identified a phosphorothioate oligonucleotide (PS-ODN) that inhibited epidermal growth factor receptor tyrosine kinase (TK) activity both in cell fractions and in intact A431 cells. Since ODN-based TK inhibitors may have anti-cancer applications and may also help understand the non-antisense mediated effects of PS-ODNs, we have further studied the sequence and chemistry requirements of the parent PS-ODN (sequence: 5′-GGA GGG TCG CAT CGC-3′) as a sequence-dependent TK inhibitor. Sequence deletion and substitution studies revealed that the 5′-terminal GGA GGG hexamer sequence in the parent compound was essential for anti-TK activity in A431 cells. Site-specific substitution of any G with a T in this 5′-terminal motif within the parent compound caused a significant loss in anti-TK activity. The fully PS-modified hexameric motif alone exhibited equipotent activity as the parent 15-mer whereas phosphodiester (PO) or 2′- O-methyl-modified versions of this motif had significantly reduced anti-TK activity. Further, T substitutions within the two 5′-terminal G residues of the hexameric PS-ODN to produce a sequence, TTA GGG, representing the telomeric repeats in human chromosomes, also did not exhibit a significant anti-TK activity. Multiple repeats of the active hexameric motif in PS-ODNs resulted in more potent inhibitors of TK activity than the parent ODN. These results suggested that PS-ODNs, but not PO or 2′- O-methyl modified ODNs, containing the GGA GGG motif can exert potent anti-TK activity which may be desirable in some anti-tumor applications. Additionally, the presence of this previously unidentified motif in antisense PS-ODN constructs may contribute to their biological effects in vitro and in vivo and should be accounted for in the design of the PS-modified antisense ODNs.
doi_str_mv 10.1016/S0006-2952(02)00985-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71897212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295202009851</els_id><sourcerecordid>71897212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-757352d0b1125404373dfe33af1d4df8b34780be1e810f324535b8eb2ae78ebe3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6E5RcFD20ppLuSea0yLK7CgseVs8hnVTcaHcyJpmBAX-8aWdwj0JBUcVTX28R8hLYe2Cw_nDHGFt3fDPwt4y_Y2yjhg4ekRUoKVp6rR6T1T_kjDwr5ccSqjU8JWfAAZiQakV-3-GvHUaL1ERH7T3OodR8oLmlQ8YZYy3Up0wNjWmPEzXbambMwdI0he8p7uyEqQaHNMT7MIba2OTp1c1162Fxu8T1kFMJEenPEE1po2wN-1APz8kTb6aCL07-nHy7vvp6-am7_XLz-fLjbWfFBmonBykG7tgIwIee9UIK51EI48H1zqtR9FKxEQEVMC94P4hhVDhyg7I5FOfkzbHvNqd2bam6XWlxmkzEtCtagtpIDryBwxG0beGS0ettDrPJBw1ML7Lrv7LrRVPNmi2ya2h1r04DduOM7qHqpHMDXp8AU6yZfDbRhvLACcUUY0PjLo4cNjn2AbMuNizvce0ZtmqXwn9W-QNOWqEk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71897212</pqid></control><display><type>article</type><title>Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Akhtar, Saghir ; Dunnion, Debbie ; Poyner, David ; Ackroyd, John ; Bibby, Mike ; Double, John</creator><creatorcontrib>Akhtar, Saghir ; Dunnion, Debbie ; Poyner, David ; Ackroyd, John ; Bibby, Mike ; Double, John</creatorcontrib><description>We have previously identified a phosphorothioate oligonucleotide (PS-ODN) that inhibited epidermal growth factor receptor tyrosine kinase (TK) activity both in cell fractions and in intact A431 cells. Since ODN-based TK inhibitors may have anti-cancer applications and may also help understand the non-antisense mediated effects of PS-ODNs, we have further studied the sequence and chemistry requirements of the parent PS-ODN (sequence: 5′-GGA GGG TCG CAT CGC-3′) as a sequence-dependent TK inhibitor. Sequence deletion and substitution studies revealed that the 5′-terminal GGA GGG hexamer sequence in the parent compound was essential for anti-TK activity in A431 cells. Site-specific substitution of any G with a T in this 5′-terminal motif within the parent compound caused a significant loss in anti-TK activity. The fully PS-modified hexameric motif alone exhibited equipotent activity as the parent 15-mer whereas phosphodiester (PO) or 2′- O-methyl-modified versions of this motif had significantly reduced anti-TK activity. Further, T substitutions within the two 5′-terminal G residues of the hexameric PS-ODN to produce a sequence, TTA GGG, representing the telomeric repeats in human chromosomes, also did not exhibit a significant anti-TK activity. Multiple repeats of the active hexameric motif in PS-ODNs resulted in more potent inhibitors of TK activity than the parent ODN. These results suggested that PS-ODNs, but not PO or 2′- O-methyl modified ODNs, containing the GGA GGG motif can exert potent anti-TK activity which may be desirable in some anti-tumor applications. Additionally, the presence of this previously unidentified motif in antisense PS-ODN constructs may contribute to their biological effects in vitro and in vivo and should be accounted for in the design of the PS-modified antisense ODNs.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/S0006-2952(02)00985-1</identifier><identifier>PMID: 12110378</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Antineoplastic agents ; Antisense oligodeoxynucleotide ; Aptamer ; Base Sequence ; Biological and medical sciences ; Disease Models, Animal ; ErbB Receptors - antagonists &amp; inhibitors ; ErbB Receptors - genetics ; ErbB Receptors - metabolism ; General aspects ; Medical sciences ; Mice ; Mice, Nude ; Mutation ; Neoplasm Transplantation ; Neoplasms, Experimental - prevention &amp; control ; Oligodeoxyribonucleotides, Antisense - chemistry ; Oligodeoxyribonucleotides, Antisense - pharmacology ; Oligodeoxyribonucleotides, Antisense - therapeutic use ; Pharmacology. Drug treatments ; Phosphorothioate ; Protein-Tyrosine Kinases - antagonists &amp; inhibitors ; Receptor tyrosine kinase inhibitor ; Thionucleotides - chemistry ; Thionucleotides - pharmacology ; Thionucleotides - therapeutic use ; Xenograft Model Antitumor Assays</subject><ispartof>Biochemical pharmacology, 2002-06, Vol.63 (12), p.2187-2195</ispartof><rights>2002</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-757352d0b1125404373dfe33af1d4df8b34780be1e810f324535b8eb2ae78ebe3</citedby><cites>FETCH-LOGICAL-c391t-757352d0b1125404373dfe33af1d4df8b34780be1e810f324535b8eb2ae78ebe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006295202009851$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13808005$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12110378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akhtar, Saghir</creatorcontrib><creatorcontrib>Dunnion, Debbie</creatorcontrib><creatorcontrib>Poyner, David</creatorcontrib><creatorcontrib>Ackroyd, John</creatorcontrib><creatorcontrib>Bibby, Mike</creatorcontrib><creatorcontrib>Double, John</creatorcontrib><title>Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>We have previously identified a phosphorothioate oligonucleotide (PS-ODN) that inhibited epidermal growth factor receptor tyrosine kinase (TK) activity both in cell fractions and in intact A431 cells. Since ODN-based TK inhibitors may have anti-cancer applications and may also help understand the non-antisense mediated effects of PS-ODNs, we have further studied the sequence and chemistry requirements of the parent PS-ODN (sequence: 5′-GGA GGG TCG CAT CGC-3′) as a sequence-dependent TK inhibitor. Sequence deletion and substitution studies revealed that the 5′-terminal GGA GGG hexamer sequence in the parent compound was essential for anti-TK activity in A431 cells. Site-specific substitution of any G with a T in this 5′-terminal motif within the parent compound caused a significant loss in anti-TK activity. The fully PS-modified hexameric motif alone exhibited equipotent activity as the parent 15-mer whereas phosphodiester (PO) or 2′- O-methyl-modified versions of this motif had significantly reduced anti-TK activity. Further, T substitutions within the two 5′-terminal G residues of the hexameric PS-ODN to produce a sequence, TTA GGG, representing the telomeric repeats in human chromosomes, also did not exhibit a significant anti-TK activity. Multiple repeats of the active hexameric motif in PS-ODNs resulted in more potent inhibitors of TK activity than the parent ODN. These results suggested that PS-ODNs, but not PO or 2′- O-methyl modified ODNs, containing the GGA GGG motif can exert potent anti-TK activity which may be desirable in some anti-tumor applications. Additionally, the presence of this previously unidentified motif in antisense PS-ODN constructs may contribute to their biological effects in vitro and in vivo and should be accounted for in the design of the PS-modified antisense ODNs.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antisense oligodeoxynucleotide</subject><subject>Aptamer</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>ErbB Receptors - antagonists &amp; inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>ErbB Receptors - metabolism</subject><subject>General aspects</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Mutation</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms, Experimental - prevention &amp; control</subject><subject>Oligodeoxyribonucleotides, Antisense - chemistry</subject><subject>Oligodeoxyribonucleotides, Antisense - pharmacology</subject><subject>Oligodeoxyribonucleotides, Antisense - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphorothioate</subject><subject>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</subject><subject>Receptor tyrosine kinase inhibitor</subject><subject>Thionucleotides - chemistry</subject><subject>Thionucleotides - pharmacology</subject><subject>Thionucleotides - therapeutic use</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6E5RcFD20ppLuSea0yLK7CgseVs8hnVTcaHcyJpmBAX-8aWdwj0JBUcVTX28R8hLYe2Cw_nDHGFt3fDPwt4y_Y2yjhg4ekRUoKVp6rR6T1T_kjDwr5ccSqjU8JWfAAZiQakV-3-GvHUaL1ERH7T3OodR8oLmlQ8YZYy3Up0wNjWmPEzXbambMwdI0he8p7uyEqQaHNMT7MIba2OTp1c1162Fxu8T1kFMJEenPEE1po2wN-1APz8kTb6aCL07-nHy7vvp6-am7_XLz-fLjbWfFBmonBykG7tgIwIee9UIK51EI48H1zqtR9FKxEQEVMC94P4hhVDhyg7I5FOfkzbHvNqd2bam6XWlxmkzEtCtagtpIDryBwxG0beGS0ettDrPJBw1ML7Lrv7LrRVPNmi2ya2h1r04DduOM7qHqpHMDXp8AU6yZfDbRhvLACcUUY0PjLo4cNjn2AbMuNizvce0ZtmqXwn9W-QNOWqEk</recordid><startdate>20020615</startdate><enddate>20020615</enddate><creator>Akhtar, Saghir</creator><creator>Dunnion, Debbie</creator><creator>Poyner, David</creator><creator>Ackroyd, John</creator><creator>Bibby, Mike</creator><creator>Double, John</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020615</creationdate><title>Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity</title><author>Akhtar, Saghir ; Dunnion, Debbie ; Poyner, David ; Ackroyd, John ; Bibby, Mike ; Double, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-757352d0b1125404373dfe33af1d4df8b34780be1e810f324535b8eb2ae78ebe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antisense oligodeoxynucleotide</topic><topic>Aptamer</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>ErbB Receptors - antagonists &amp; inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>ErbB Receptors - metabolism</topic><topic>General aspects</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Mutation</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms, Experimental - prevention &amp; control</topic><topic>Oligodeoxyribonucleotides, Antisense - chemistry</topic><topic>Oligodeoxyribonucleotides, Antisense - pharmacology</topic><topic>Oligodeoxyribonucleotides, Antisense - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphorothioate</topic><topic>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</topic><topic>Receptor tyrosine kinase inhibitor</topic><topic>Thionucleotides - chemistry</topic><topic>Thionucleotides - pharmacology</topic><topic>Thionucleotides - therapeutic use</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akhtar, Saghir</creatorcontrib><creatorcontrib>Dunnion, Debbie</creatorcontrib><creatorcontrib>Poyner, David</creatorcontrib><creatorcontrib>Ackroyd, John</creatorcontrib><creatorcontrib>Bibby, Mike</creatorcontrib><creatorcontrib>Double, John</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akhtar, Saghir</au><au>Dunnion, Debbie</au><au>Poyner, David</au><au>Ackroyd, John</au><au>Bibby, Mike</au><au>Double, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2002-06-15</date><risdate>2002</risdate><volume>63</volume><issue>12</issue><spage>2187</spage><epage>2195</epage><pages>2187-2195</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>We have previously identified a phosphorothioate oligonucleotide (PS-ODN) that inhibited epidermal growth factor receptor tyrosine kinase (TK) activity both in cell fractions and in intact A431 cells. Since ODN-based TK inhibitors may have anti-cancer applications and may also help understand the non-antisense mediated effects of PS-ODNs, we have further studied the sequence and chemistry requirements of the parent PS-ODN (sequence: 5′-GGA GGG TCG CAT CGC-3′) as a sequence-dependent TK inhibitor. Sequence deletion and substitution studies revealed that the 5′-terminal GGA GGG hexamer sequence in the parent compound was essential for anti-TK activity in A431 cells. Site-specific substitution of any G with a T in this 5′-terminal motif within the parent compound caused a significant loss in anti-TK activity. The fully PS-modified hexameric motif alone exhibited equipotent activity as the parent 15-mer whereas phosphodiester (PO) or 2′- O-methyl-modified versions of this motif had significantly reduced anti-TK activity. Further, T substitutions within the two 5′-terminal G residues of the hexameric PS-ODN to produce a sequence, TTA GGG, representing the telomeric repeats in human chromosomes, also did not exhibit a significant anti-TK activity. Multiple repeats of the active hexameric motif in PS-ODNs resulted in more potent inhibitors of TK activity than the parent ODN. These results suggested that PS-ODNs, but not PO or 2′- O-methyl modified ODNs, containing the GGA GGG motif can exert potent anti-TK activity which may be desirable in some anti-tumor applications. Additionally, the presence of this previously unidentified motif in antisense PS-ODN constructs may contribute to their biological effects in vitro and in vivo and should be accounted for in the design of the PS-modified antisense ODNs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12110378</pmid><doi>10.1016/S0006-2952(02)00985-1</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-2952
ispartof Biochemical pharmacology, 2002-06, Vol.63 (12), p.2187-2195
issn 0006-2952
1873-2968
language eng
recordid cdi_proquest_miscellaneous_71897212
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Antineoplastic agents
Antisense oligodeoxynucleotide
Aptamer
Base Sequence
Biological and medical sciences
Disease Models, Animal
ErbB Receptors - antagonists & inhibitors
ErbB Receptors - genetics
ErbB Receptors - metabolism
General aspects
Medical sciences
Mice
Mice, Nude
Mutation
Neoplasm Transplantation
Neoplasms, Experimental - prevention & control
Oligodeoxyribonucleotides, Antisense - chemistry
Oligodeoxyribonucleotides, Antisense - pharmacology
Oligodeoxyribonucleotides, Antisense - therapeutic use
Pharmacology. Drug treatments
Phosphorothioate
Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor tyrosine kinase inhibitor
Thionucleotides - chemistry
Thionucleotides - pharmacology
Thionucleotides - therapeutic use
Xenograft Model Antitumor Assays
title Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T09%3A40%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequence%20and%20chemistry%20requirements%20for%20a%20novel%20aptameric%20oligonucleotide%20inhibitor%20of%20EGF%20receptor%20tyrosine%20kinase%20activity&rft.jtitle=Biochemical%20pharmacology&rft.au=Akhtar,%20Saghir&rft.date=2002-06-15&rft.volume=63&rft.issue=12&rft.spage=2187&rft.epage=2195&rft.pages=2187-2195&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/S0006-2952(02)00985-1&rft_dat=%3Cproquest_cross%3E71897212%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71897212&rft_id=info:pmid/12110378&rft_els_id=S0006295202009851&rfr_iscdi=true